引用本文:夏小艳,周小明(综述),李耀军(审校).SIRT1在肿瘤耐药中的作用研究进展[J].中国临床新医学,2017,10(9):930-933.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2008次   下载 1649 本文二维码信息
码上扫一扫!
分享到: 微信 更多
SIRT1在肿瘤耐药中的作用研究进展
夏小艳,周小明(综述),李耀军(审校)
410100 湖南,长沙卫生职业学院科研处(夏小艳),临床医技系(李耀军);410000 长沙,湖南中医药大学第一附属医院中医内科(周小明)
摘要:
[摘要] 恶性肿瘤的多药耐药是目前治疗的瓶颈。表观遗传学与肿瘤多药耐药之间的关系引起了越来越多研究者的关注,作为表观遗传学领域的后起新星沉默信息调节因子1(SIRT1)与肿瘤多药耐药的关系成为近年来的研究热点。SIRT1是细胞生理及病理过程如细胞增值、分化、DNA损伤与应激反应、衰老及肿瘤的形成的关键调节器。该文对SIRT1对肿瘤作用及耐药性进行文献回顾,为寻找SIRT1调节剂特别是恶性肿瘤的治疗提供新思路。
关键词:  沉默信息调节因子1  肿瘤多药耐药  治疗
DOI:10.3969/j.issn.1674-3806.2017.09.32
分类号:R 730
基金项目:湖南省教育厅科学研究项目(编号:16C0127)
Research progress on the role of SIRT1 in tumor resistance
XIA Xiao-yan, ZHOU Xiao-ming, LI Yao-jun
Department of Scientific Research, Changsha Health Vocational College, Hunan 410100, China
Abstract:
[Abstract] Multidrug resistance of malignant tumors is the bottleneck of anti-tumor treatment at present. More and more researchers pay attention to the relationship between epigenetics and multidrug resistance. As a promising new star in the field of epigenetics study, Silent information regulator 1(SIRT1) has become a hot research topic in recent years because of its relationship with multidrug resistance of tumors. SIRT1 is a key regulator of cellular physiology and pathological processes such as cell proliferation, differentiation, DNA damage and stress response, aging and tumor formation. In this paper, we review the anti-tumor effect of SIRT1 and its drug resistance to provide a new idea for the treatment of malignant tumors using SIRT1 modulators.
Key words:  Silent information regulator 1  Multidrug resistance of tumor  Treatment